uniQure: Why Waiting For Clarity Beats Chasing The Next Step Jump
Source: SeekingAlpha
2025-12-18 08:33:33 ET
uniQure ( QURE ) had a wild ride from September to November, first surging vertically as approval prospects looked compelling due to promising AMT-130 gene-therapy results (showing slowing of Huntington's disease progression in mid-stage data). The fall was equally sharp and material as FDA indicated that the Phase I/II data were unlikely to support a Biologics License Application (BLA) as the primary evidence....
Read the full article on Seeking Alpha
For further details see:
uniQure: Why Waiting For Clarity Beats Chasing The Next Step Jump
uniQure N.V.
NASDAQ: QURE
QURE Trading
18.55% G/L:
$20.035 Last:
2,309,692 Volume:
$17.97 Open:
QURE Latest News
April 30, 2026 07:05:00 am
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease
QURE Stock Data
$1,555,111,367
59,307,892
N/A
61
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
